

Index

- abacavir 424
- absence seizures 264, 265
- abstract attitude 20
- acetylcholine receptor systems, dementia with
 - Lewy bodies 481
- acute and transient psychotic disorders (ATPD)
 - age at onset 103
 - antipsychotic medication 111
 - course 105–7
 - duration of treatment 111
 - epidemiology 535
 - gender 102–3
 - genetics 108–9
 - neurochemical abnormalities 108
 - neuroimaging 107
 - neuropathology 107
 - outcome 106
 - presentation 103–4
 - progression 105–7
 - psychogenic 110
 - reactive 110
 - serine 108
 - treatment 110–2. *See also* brief psychotic disorder
- acyclovir, herpes simplex encephalitis 321, 322
- addiction hypothesis, primary 374–5
- adrenocortical insufficiency 356–7
- adrenoleukodystrophy, X-linked 353–7
 - age of onset 354
 - brain changes 355–6
 - course 354–5
 - environmental risk factors 356
 - epidemiology 354
 - genetic factors 356
 - neurochemical abnormalities 356
 - neuroimaging 355–6
 - neuropathology 355–6
 - presentation 354
 - progression 354–5
 - temporal lobe pathology 535–6
 - treatment 356–7
 - very long chain fatty acids 355–6
- adrenomyeloneuropathy 355
- affective disorders
 - catatonia 234
 - human immunodeficiency virus 318
- affective flattening, autism 238–9
- aggression
 - Alzheimer's disease 458
 - delusional disorder 121
- alcoholism, delusional disorder association 127–8
- alprazolam 402
- Alzheimer's disease
 - dementia with Lewy bodies linkage 482
 - prodromal stage 160
 - visual hallucinations 524, 525
- Alzheimer's disease-related psychosis 455–6
 - age of onset 456–7
 - associated symptoms 458
 - brain changes 459
 - course 458–9
 - epidemiology 456, 537
 - genetic factors 461–4
 - linkage analysis 461–2
 - neurochemical abnormalities 460
 - neuropathology 459
 - onset of psychosis
 - presentation 457–8
 - progression 458–9
 - putative psychosis genes 462–3
 - symptoms 457–8
 - treatment 464–6
- amantadine
 - Parkinson's disease 493, 502
 - psychosis risk 423
- amino acids, brief and acute psychoses 108
- amitriptyline 430
- amphetamines 434
- Andermann syndrome 207
- angel's trumpet 431
- angiotensin converting enzyme (ACE) inhibitors
 - 411
- angiotensin receptor blockers 411
- anosognosia 288
- antibiotics
 - Lyme disease treatment 325
 - psychosis induction 410, 426–7
 - syphilis treatment 328–9

558 Index

- anticholinergic medication 423–4
 - cholinergic rebound 432–3
 - Parkinson's disease 493
 - psychosis induction 430–1
- anticonvulsants
 - bipolar disorder treatment 147
 - cerebrovascular accident 298–9
 - corticosteroid-induced psychosis 419
 - traumatic brain injury 255, 256
 - visual hallucinations 525
- antidepressant-induced psychosis 407, 410
 - neurochemistry 409
 - presentation 409
 - treatment 410
- antidepressants
 - bipolar disorder 147
 - cerebrovascular accident 299
 - major depression 180–3
 - psychosis induction 407–10
 - serotonin and norepinephrine combination 408
- anti-epileptic medication-induced psychosis 420–2
- antimalarial medication, psychosis induction 427–8
- antimycobacterial medication 429–30
- antipsychotics
 - Alzheimer's disease 464–5
 - bipolar disorder treatment 147
 - brain tumor psychosis 310–1
 - brief and acute psychoses 111
 - cerebrovascular accident 298–9
 - delusional disorder 130–1
 - epilepsy with schizophrenia-like psychosis 278
 - human immunodeficiency virus 319
 - hyperprolactinemia 310–1
 - intellectual disabilities with psychosis 209
 - major depression 181–3
 - multiple sclerosis 343
 - Parkinson's disease-induced psychosis 502
 - schizophrenia 68
 - seizure risk 279
 - systemic lupus erythematosus 348–9
 - tardive dyskinesia 210
 - traumatic brain injury 255
- antipsychotics, atypical
 - Alzheimer's disease 465
 - bipolar disorder treatment 147
 - cannabis psychosis 376–7
 - cerebrovascular accident 298
 - corticosteroid-induced psychosis 419
 - delusional disorder 130–1
 - dementia with Lewy bodies 483
 - epilepsy with schizophrenia-like psychosis 278
 - intellectual disabilities with psychosis 209–10
 - methamphetamine-induced psychosis 401
 - multiple sclerosis 343
 - Parkinson's disease-induced psychosis 502–4
 - schizoaffective disorder 87–8
 - schizophrenia 50–1, 68–9
 - traumatic brain injury 255
- antisocial personality, cannabis psychosis 372, 376
- antiviral medication, psychosis induction 424–6
- anxiety
 - brief psychotic disorder 105
 - epidemiology 536
 - human immunodeficiency virus 318
 - schizophreniform disorder 105
- apathy 540–1
- apolipoprotein E4 (APOE4) allele
 - Alzheimer's disease 463–4
 - dementia with Lewy bodies 482
- aripiprazole
 - Alzheimer's disease 464–5
 - methamphetamine-induced psychosis 401
 - Parkinson's disease-induced psychosis 504
- arylsulphatase A 351, 353
- asparaginase, psychosis risk 309
- Asperger disorder 238
- attention, dementia with Lewy bodies 475–6
- autism 233–5
 - affective flattening 238–9
 - age of onset 538
 - atypical 238
 - catatonia 235, 238–42
 - catatonic variant 242
 - cognitive deficits 237
 - conceptualization 233–42
 - course 538–9
 - diagnosis 236–7
 - electroconvulsive therapy 241
 - epilepsy association 236–7
 - genetic factors 236
 - hallucinations 238–9
 - intellectual disabilities differential diagnosis 199
 - medical disorders 236
 - neurological disorders 236
 - prevalence 236
 - psychosis 234–5, 237
 - schizophrenia association 237–9
 - speech 239–40
 - symptom overlap with catatonia 241
 - terminology 235
 - thought disorders 238–9
- autosomal chromosome anomalies, psychotic symptoms 208
- avoidant personality disorder 127–8
- axonal pathology in multiple sclerosis 341
- azathioprine 347–8
- baclofen 438
- bacterial infections 322–9
- behavioral disturbance
 - cocaine-induced psychosis 384, 387
 - metachromatic leukodystrophy 351
 - X-linked adrenoleukodystrophy 354
- benzodiazepines
 - epilepsy with schizophrenia-like psychosis 278–9
 - methamphetamine-induced psychosis 401
 - psychosis induction 439
 - traumatic brain injury 255
- benztropin 430
 - Parkinson's disease 493

Cambridge University Press

978-0-521-85056-8 - The Spectrum of Psychotic Disorders: Neurobiology, Etiology, and Pathogenesis

Edited by Daryl Fujii and Iqbal Ahmed

Index

[More information](#)**559 Index**

- beta blockers 411
- biogenic amines
 - depression hypothesis 411
 - hallucinations 494
- bipolar disorder 138
 - age of onset 139–40
 - brain abnormalities 142–4
 - course 141–2
 - depression treatment 147
 - epidemiology 138–9, 536
 - GABA abnormalities 144
 - gender differences 140
 - genetic factors 145, 543
 - major depression
 - association 178
 - conversion 159
 - mania 147–8
 - multiple sclerosis association 146
 - neurochemistry 144
 - neuropathology 142–4
 - outcome 142
 - post-partum psychosis association 146
 - presentation 140–1
 - prevalence 138–9
 - progression 141–2
 - psychosocial functioning 142
 - psychotic/nonpsychotic brain differences 143–4
 - recurrence 141–2
 - schizoaffective disorder differential diagnosis 81
 - socio-environmental risk factors 146
 - subtypes 138
 - symptoms 139–41
 - treatment 146–8
 - velo-cardio-facial syndrome 220–2
 - white matter abnormalities 143
 - young people 140
- bone marrow transplantation, X-linked
 - adrenoleukodystrophy 356–7
- Borrelia burgdorferi* 323
- brain
 - lesions in neurological syndromes 7–8
 - radiation effects 308–10
- brain changes
 - Alzheimer's disease 459
 - auditory hallucinations 525
 - cocaine-induced psychosis 385–6
 - dementia with Lewy bodies 480
 - imbalances in systems 546–8
 - methamphetamine-induced psychosis 396–8
 - multiple sclerosis 339–41
 - neuropathological mechanisms 548
 - Parkinson's disease-related psychosis 491, 498
 - psychosis 7–9
 - severity 548
 - systemic lupus erythematosus 346
 - temporal lobe pathology 535–6, 541–2
 - white matter 143, 222–3, 541–2
 - X-linked adrenoleukodystrophy 355–6
- brain injury, traumatic 249–50
 - age of onset 251
 - classification 256
 - cognitive impairment 252
 - contribution to psychosis development 257–8
 - course 252–4, 256, 538–9
 - delusions 251
 - diagnosis 250–1
 - disconnection syndrome of memory 297
 - dopaminergic system 254
 - environmental risk factors 255
 - epidemiology 250–1
 - gender differences 254
 - genetic factors 254–5
 - hallucinations 251, 259
 - incidence 250
 - kindling 258–9
 - latency 252, 253, 256, 258–9
 - neural network changes 259
 - neurochemistry 254
 - neuroleptics 254–6
 - neuropathology 254
 - onset 252–3
 - pathophysiological processes 259
 - presentation 251–2
 - primary cause of psychosis 256
 - prodromal symptoms 253
 - progression 252–4, 256, 538–9
 - reduplicative amnesia 297
 - seizure disorders 251–2
 - sensitization 258–9
 - severity of injury 250
 - temporal lobe pathology 535–6
 - treatment 255, 256
 - unrelated to psychosis development 258
- brain tumors 302–3
 - age of onset 304–5
 - antipsychotics 310–1
 - course 305–6
 - diagnosis 305–6
 - electroconvulsive therapy 311
 - epidemiology 303–4
 - genetic factors 308–9
 - hallucinations 305, 307
 - immunosuppression 308–9
 - incidence 302
 - location 303, 307
 - neurochemical abnormalities 308
 - neuroimaging 306
 - neuropathology 306–8
 - presentation 304–5
 - prevalence 303
 - prognosis 305–6
 - prolactin level 306
 - psychiatric patients 303–4
 - psychiatric symptoms 304
 - psychosocial risk factors 309
 - surgery 309
 - symptoms 304–6
 - mechanisms 306
 - treatment 303
 - of psychosis 309–11
 - psychosis risk 309
 - types 302

- brief and acute psychoses
 - antipsychotic medication 111
 - duration of treatment 111
 - treatment 110–2. *See also* acute and transient psychotic disorders (ATPD); brief psychotic disorder; schizophreniform disorder
- brief psychotic disorder
 - age at onset 103
 - amino acids 108
 - antecedent fever 109–10
 - anxiety 105
 - course 105–7
 - criteria 97–101
 - developing countries 102
 - diagnostic stability 106
 - diagnostic systems 97–101
 - differential diagnosis 106–7
 - epidemiology 101–3, 535
 - gender 102–3
 - genetics 108–9
 - incidence 101–2
 - mood bipolarity 104
 - neurochemical abnormalities 108
 - neuroimaging 107
 - neuropathology 107
 - outcome 106
 - presentation 103–5
 - prevalence 101–2
 - progression 105–7
 - psychogenic 110
 - psychotic episode duration 105–6
 - rapid onset 538–9
 - reactive 110
 - symptoms 104
- brimonidine tartrate 411
- bromocriptine
 - Parkinson's disease 492–3
 - psychosis risk 309, 423
- bupropion
 - methamphetamine-induced psychosis 400–1
 - psychosis induction 407–9
- caffeine 434
- calcitonin 526
- calcium, intracellular free 319
- calcium channel blockers 412
- cannabinoid system 374–5
- cannabinoids 373
- cannabis psychosis 369
 - brain changes 372–3
 - course 371–2
 - epidemiology 370
 - gender differences 370
 - genetic factors 375–6
 - mania 370–1
 - neurochemical abnormalities 373–5
 - neuropathology 372–3
 - paranoia 370–1
 - personality traits 376
 - presentation 370–1
 - progression 371–2
 - schizophrenia 372, 376
 - symptomatology 370–1
 - treatment 376–7
- Capgras' syndrome 288–90, 297
 - dementia with Lewy bodies 477
- carbamazepine
 - bipolar disorder treatment 147
 - brain tumor psychosis 310
 - cannabis psychosis 376–7
 - Fregoli's syndrome 291
 - multiple sclerosis 342, 343
 - psychosis induction 420
 - schizoaffective disorder 87
 - visual hallucinations 525
 - X-linked adrenoleukodystrophy 357
- cardiovascular medications
 - epidemiology of psychosis 412
 - neurochemistry of psychosis 412
 - psychosis induction 411–13
- catatonia
 - affective disorders 234
 - autism 235, 238–42
 - childhood 234
 - electroconvulsive therapy 241
 - intellectual disabilities with psychosis 204–5
 - mania 234
 - symptom overlap with autism 241
- catechol-O-methyltransferase (COMT) gene 27, 542
 - Alzheimer's disease 462–3
 - cannabis psychosis 376
 - chromosome 22q 218–19
 - locus 224
 - schizophrenia association 225
 - velo-cardio-facial syndrome 224–5, 542–3
- celecoxib 414
- cerebellar atrophy 207
- cerebral insult, delusional disorder association 128
- cerebrospinal fluid, ventricular, velo-cardio-facial syndrome 223
- cerebrovascular accident, psychosis after 285–6
 - age of onset 287
 - Capgras' syndrome 288–90, 297
 - confusion 293
 - course 295
 - delusional misidentification 288–9, 295
 - delusions 292, 293, 295–6
 - with disorientation for place 289–90
 - dopamine system 298
 - epidemiology 286–7
 - Fregoli's syndrome 288–91
 - hallucinations 292–6
 - latency 295
 - mania 292
 - MELAS syndrome 297–8
 - neurochemical abnormalities 298
 - neuroimaging 287
 - neuropathology 295–8
 - presentation 288–95

561 Index

- prognosis 295
- rapid onset 538–9
- reduplicative paramnesia 288–90
- schizophreniform disorder 296
- seizures 296–7
- symptom clusters 288
- symptoms 291–5
- temporal lobe pathology 535–6
- treatment 298–9
- Charles Bonnet syndrome 515–16
- chemotherapy, psychosis risk 309, 440–2
- childhood disintegrative disorder 235
- children/young people
 - autism 234–5
 - catatonia 235
 - bipolar disorder 140
 - catatonia 234, 235
 - ictal psychosis onset 264
 - metachromatic leukodystrophy 350
 - psychosis onset 538
 - schizoaffective disorder 80–1
 - schizophrenia 39–40
 - age of onset 43, 538
 - autism symptoms 240
 - comorbidity 41–2
 - course 46–7
 - ethnicity 42–3
 - gender distribution 41
 - genetic factors 48–9
 - neurochemical abnormalities 48
 - neuropathology 47–8
 - obstetric complications 49
 - pervasive development disorders 235–7
 - presentation 43–5
 - prevalence 40–1
 - progression 46–7
 - treatment 49–53
 - University of Hawaii Child and Adolescent Thought Disorders Program 51–3
 - X-linked adrenoleukodystrophy 353–7.
 - See also* velo-cardio-facial syndrome
- chimeric assimilation 288–9
- chlorpromazine
 - bipolar disorder treatment 147
 - systemic lupus erythematosus 348–9
 - traumatic brain injury 255
- choline acetyltransferase (ChAT) 497
- dementia with Lewy bodies 481
- cholinergic deficit, dementia with Lewy bodies 481
- cholinergic rebound 432
- cholinergic receptors, muscarinic 460
- cholinesterase inhibitors
 - Alzheimer's disease 465–6
 - cerebrovascular accident 299
 - dementia with Lewy bodies 483
 - Parkinson's disease-induced psychosis 504–5
- chromosome 22
 - deletion in velo-cardio-facial syndrome 208
 - mutation in metachromatic leukodystrophy 353
- chromosome 22q 218–19
- COMT gene 224
- microdeletion
 - schizophrenia 220
 - velo-cardio-facial syndrome 218–19
- cimetidine, psychosis induction 435–6
- ciprofloxacin 426
- clonazepam, systemic lupus erythematosus 348–9
- clozapine 50
 - autism with catatonia 241–2
 - bipolar disorder treatment 147
 - cholinergic rebound 432–3
 - cocaine-induced psychosis 387–8
 - intellectual disabilities with psychosis 209, 210
 - Parkinson's disease-induced psychosis 503
 - tardive dyskinesia 210
 - X-linked adrenoleukodystrophy 357
- cocaine 382
- cocaine-induced psychosis 382
 - age of onset 383
 - behavioral disturbance 384, 387
 - brain changes 385–6
 - course 385
 - epidemiology 382–3
 - genetic risk factors 386–7
 - mental disorder prior history 387
 - neurochemistry 386
 - neuroimaging 385–6
 - neuropathology 385–6
 - P50 sensory gating deficiencies 387
 - presentation 383–5
 - schizophrenia 384
 - treatment 387–8
- cognitive disintegration, intellectual disabilities
 - with psychosis 200–1
- cognitive impairment 541
 - Alzheimer's disease 458–9
 - autism 237
 - cocaine-induced psychosis 384–5
 - dementia with Lewy bodies 475–6
 - intellectual disabilities with psychosis 206–7
 - methamphetamine-induced psychosis 395–6
 - traumatic brain injury 252
- cognitive rehabilitation, schizophrenia 32
- cognitive-behavioral interventions
 - delusional disorder 129–30
 - schizophrenia 30–1
- combivir 424
- compliance with medication, schizophrenia 69
- confusion, cerebrovascular accident 293
- congenital syndromes, intellectual disabilities with psychosis 207
- cortical reassignment 521–2
- corticosteroids
 - multiple sclerosis 342
 - psychosis
 - induction 418–19, 542
 - risk 309, 342, 348
 - systemic lupus erythematosus 348
- cortisol, major depression 176–8
- Creutzfeldt–Jakob disease (CJD) 330
- cyclobenzaprine 438, 439

562 Index

- cyclophosphamide 347–8
- cyclothymic disorder 138
 - velo-cardio-facial syndrome 220
- cyproheptadine 436–7

- deep brain stimulation, Parkinson's disease 505
- delirium
 - anticholinergic medication 430–1
 - human immunodeficiency virus 317–18
 - infections 316–17
 - medication-induced psychosis 406–7
 - parkinsonian medication 423
- delusional disorder 116–18
 - absence of psychiatric features 121
 - age of onset 119, 124
 - aggression 121
 - antipsychotic treatment 130–1
 - behavioral symptoms 122
 - chronic forms 125
 - clinical features 121
 - cognitive-behavioral therapy 129–30
 - comorbidity 122
 - course 123–5
 - emotional symptoms 122
 - epidemiology 118–19, 535
 - gender differences 119
 - genetic factors 126–8
 - hallucinations 122
 - imaging 126
 - incidence 118–19
 - jealous type 119
 - latency 123
 - misidentification 288–9, 295
 - negative 121
 - neurochemistry 126
 - neuropathology 125–6
 - neuropsychological findings 122–3
 - onset 119–20
 - organic 125
 - persecutory type 119
 - premorbid risk factors 123
 - presentation 119–23
 - initial 123–4
 - psychotic symptoms 124
 - prevalence 118–19
 - prodrome 124–5
 - progression 123–5
 - psychosocial treatment 129–30
 - psychotic disorder continuum 120–1
 - rapid onset 538–9
 - somatic treatment 130–1
 - somatic type 119
 - symptoms 122
 - positive 121
 - presentation 124
 - treatment 128–31
- delusions 3, 285, 539
 - Alzheimer's disease 456–8
 - autism with catatonia 240–1
 - bipolar disorder 138–41, 145
 - brief interictal psychosis 270
 - categorization 120–1
 - cerebrovascular accident 292, 293, 295–6
 - cocaine-induced psychosis 383–4
 - dementia with Lewy bodies 477
 - episodic 163
 - erotomania 121
 - grandiosity 383–4, 538
 - human immunodeficiency virus 318
 - intellectual disabilities with psychosis 198–9
 - jealous 119–21, 124, 125
 - major depression 160–1, 163
 - methamphetamine-induced psychosis 394–5
 - multiple sclerosis 338–9
 - neuropathology 125
 - paranoid 293
 - brief interictal psychosis 270
 - bupropion psychosis 407–8
 - cocaine-induced psychosis 383–4, 387
 - parkinsonian medication 423
 - Parkinson's disease-related psychosis 495
 - persecution 119–21, 124
 - traumatic brain injury 251
 - preoccupation 123–4
 - schizophrenia 43–4
 - somatic 119–21, 124, 288
 - traumatic brain injury 251
- dementia
 - cognitive impairment 541
 - Creutzfeldt–Jakob disease 330
 - epidemiology 537
 - human immunodeficiency virus 318
 - major depression with psychosis 174–5
 - neurosyphilis 327
 - psychosis 286
- dementia with Lewy bodies 472–4
 - age of onset 474–5
 - Alzheimer's disease linkage 482
 - brain changes 480
 - course 477–8
 - diagnostic criteria 473
 - epidemiology 474, 535, 537
 - gender differences 474
 - genetic factors 481–2, 484
 - neurochemistry 480–1, 484, 497–8
 - neuropathology 478–80, 483–4
 - presentation 475–7, 483
 - progression 477–8
 - symptoms 475–7, 483
 - treatment 482–3
- depersonalization–derealization state 371
- depression
 - Alzheimer's disease 458
 - biogenic amine hypothesis 411
 - bipolar disorder 141
 - delusional disorder comorbidity 122
 - multiple sclerosis 338, 342
 - tactile hallucinations 524–5
 - velo-cardio-facial syndrome 221–2
- depression, major with psychosis
 - age 158
 - of onset 158–60
 - antidepressants 181–3
 - antipsychotics 181–3

563 **Index**

- bipolar disorder
 - association 178
 - conversion to 159
- borderline personality disorder 161–2
- cortisol levels 176–8
- course 163–74
- delusions 160–1
 - episodic 163
- dementia 174–5
- depression subtype/variant 162
- dexamethasone suppression test 176
- disability level 165–74
- dopamine β -hydroxylase 177, 179
- dopamine D4 gene 178
- duration of depressive symptoms 163
- early-onset 158–9
- electroconvulsive therapy 180–1
- electroencephalography 175–6
- epidemiology 157–8, 536
- executive function 163
- gender differences 158
- genetic factors 178–9
- glucocorticoids 183–4
- hallucinations 160–1
- 5HT2 receptors 177
- impairment level 165
- late-onset 160
- lithium 183
- mifepristone 183–4
- negative symptoms 161
- neurochemistry 176–8
- neuropathology 174–6
- occupational impairment 165–74
- P300 event-related potentials 175
- presentation 160–3
- prevalence 158
- progression 163–74
- psychomotor disturbance 161, 163
- psychosocial assessment 184
- recurrence risk 164–5
- relapse rate 163–4
- sleep studies 175–6
- social impairment 165–74
- suicide risk 165, 166
- symptom severity 165
- treatment 180–4
- tricyclic antidepressants 180–2
- vascular risk factors 174–5
- ventricle-to-brain ratio 174
- developing countries, brief psychotic disorder/
 - schizophreniform disorders 102
- dexamethasone suppression test, major
 - depression 176
- diagnosis
 - criteria 5–6
 - psychotic disorders 4–5
 - schizophrenia 5–7
- diagnostic criteria 549
 - psychotic disorders 4
 - schizophrenia 4
 - substance-induced psychotic disorder 4–5
- diathesis stress model of schizophrenia 8
- diazepam, traumatic brain injury 255
- digoxin 411–12, 430
- dimenhydrinate 436–7
- diphenhydramine 430
- DISC1* gene 543
 - schizoaffective disorder 86–7
- disorientation for place 289–90
- disulfiram, psychosis induction 416–18
- diuretics, thiazide 412
- divalproex 147
- donepezil 504–5
- dopamine
 - cannabinoid system 374
 - dementia with Lewy bodies 481
 - parkinsonian medication psychosis 423–4
- dopamine agonists
 - Parkinson's disease 492–3
 - psychosis risk 309, 423
- dopamine β -hydroxylase (DBH)
 - disulfiram psychosis 417–18
 - major depression 177, 179
- dopamine D4 gene 178
- dopamine D4 receptor protein 126–7
- dopamine hypothesis of schizophrenia 24, 26
- dopamine receptors
 - Alzheimer's disease 460, 464
 - cannabis psychosis 375
 - polymorphisms in delusional disorder 126
- dopaminergic system 542
 - bipolar disorder 144
 - cerebrovascular accident 298
 - cocaine-induced psychosis 386
 - imbalances in systems 546–7
 - methamphetamine-induced psychosis 397–9
 - sensitization in cannabis psychosis 373–4
 - traumatic brain injury 254
 - treatment of psychosis 544
 - velo-cardio-facial syndrome 224
- doxazosin 411
- droperidol 290
- drug holidays 424
- DSM-IV nomenclature for psychosis 5–7, 549
- elderly people
 - major depression 158. *See also* schizophrenia, late life
- electroconvulsive therapy
 - autism with catatonia 241
 - brain tumors 311
 - brief and acute psychoses 110
 - epilepsy with schizophrenia-like psychosis 278–9
 - major depression 180–1
 - Parkinson's disease-induced psychosis 505
 - systemic lupus erythematosus 348–9
- electroencephalography (EEG)
 - epileptic focus laterality 275
 - ictal psychosis 265
 - major depression with psychosis 175–6
- encephalitis 316–17
- endophenotypes 8–9
- environmental factors 543

564 Index

- environmental reduplication 288–90
ephedrine 434
epilepsy
 autism association 236–7
 brief and acute psychoses 110
 complex partial 268–9
 idiopathic mendelian 266
 intellectual disabilities with psychosis 208–9
 progression 538–9
 schizophrenia association 208–9, 262
 seizures 263
 temporal lobe pathology 535–6
epilepsy with schizophrenia-like psychosis
 age of onset 538
 antipsychotic drugs 278
 brief interictal psychosis 270–1
 chronic interictal psychosis 271–9
 classification 263
 clinical features 273
 epidemiology 271–3
 epileptic focus laterality 275
 genetics 275–6
 ictal psychosis 264–6
 neuroimaging 276
 neuropathology 276–7
 pathophysiology 277–8
 postictal psychosis 266–9
 risk factors 274–5
 surgery 278–9
 treatment 278–9
erotomania delusions 121
erythema migrans 323, 324
erythropoietin, recombinant human 441–2
ethnicity in schizophrenia 42–3
 chromosome 22q 218–19
 microdeletion 220
event-related potentials, schizoaffective disorder 85
executive function, major depression 163
expressed emotion, schizophrenia 53
extra-pyramidal symptoms, HIV treatment 319
extravagant spatial localization 288–9
eye tracking deficit, smooth pursuit
 schizophrenia 226
 velo-cardio-facial syndrome 226
family services, schizophrenia 53
Fergoli's syndrome 288–9
fever in brief and acute psychoses 109–10
forced normalization 421
 brief interictal psychosis 270–1
Fregoli's syndrome 288–91
Fujii and Ahmed hypothesis for psychosis,
 neurobiological syndrome 9–10
fungal infections 330
furosemide 430
GABA 542
 bipolar disorder abnormalities 144
 glutamate imbalance 546
 schizophrenia abnormalities 144
 vigabatrin-induced psychosis 421–2
GABA_A receptors 269
galantamine 504–5
ganciclovir 424
general deficit syndrome, schizophrenia 19, 20
genetic predisposition to psychosis 8, 542–3
 environmental factors 543
glatiramer acetate in multiple sclerosis 342
glucocorticoids, major depression 183–4
glutamate
 GABA imbalance 546
 multiple sclerosis 341
 systemic lupus erythematosus 347
glutamate decarboxylase (GAD) 66
glycerphosphoethanolamine 460
grandiosity 383–4
 age of onset 538
growth hormone in schizoaffective disorder 85–6
Halle Study on Brief and Acute Psychoses
 (HASBAP). *See* schizophreniform disorder
hallucinations 3, 285, 540
 Alzheimer's disease 456–8, 524, 525
 auditory 540
 sensory impairment with psychosis 515, 516,
 518, 519, 523, 525
autism 238–9
 with catatonia 240–1
biogenic amines 494
bipolar disorder 138–41
brain tumors 305, 307
brief interictal psychosis 270
bupropion psychosis 407–8
cerebrovascular accident 292–6
cocaine-induced psychosis 383–4
delusional disorder 122
dementia with Lewy bodies 474, 476–7, 480
epidemiology 537
herbal medication 434
herpes simplex encephalitis 321
human immunodeficiency virus 318
intellectual disabilities with psychosis 202
major depression 160–1
methamphetamine-induced psychosis 394–5
multiple sclerosis 338–9
non-steroidal anti-inflammatory drugs 414
parkinsonian medication 423–4
Parkinson's disease 493–5, 524
Parkinson's disease-related psychosis 495–7
retinoids 416
schizophrenia 43–4
sensory impairment with psychosis 514
 age of onset 515–16
 course 518–19
 epidemiology 514–15
 genetic factors 523–4
 neurochemical abnormalities 523
 neuropathology 519–23
 presentation 516–18
 progression 518–19
 treatment 525–6
SSRI psychosis 408
stimulants 434

565 Index

- tactile 540
 - sensory impairment with psychosis 514–19, 521–6
- traumatic brain injury 251, 259
- visual 540
 - sensory deprivation 524, 525
 - sensory impairment with psychosis 514–21, 523
- haloperidol
 - Alzheimer's disease 464–5
 - bipolar disorder treatment 147
 - brain tumor psychosis 310–1
 - cannabis psychosis 376–7
 - corticosteroid-induced psychosis 419
 - multiple sclerosis 342, 343
 - Parkinson's disease-induced psychosis 502
 - systemic lupus erythematosus 348–9
 - traumatic brain injury 255
 - X-linked adrenoleukodystrophy 357
- herbal supplements, psychosis induction 433–4
- herpes simplex encephalitis 320–2
 - age of onset 320
 - course 321
 - epidemiology 320
 - neuropathology 321
 - presentation 321
 - prognosis 321
 - symptoms 321
 - treatment 322
- herpes simplex virus 320
- histamine H1 blockers, psychosis induction 436–7
- histamine H2 blockers 435
 - psychosis induction 435–6
- homovanillic acid
 - cannabinoid system 374
 - delusional disorder 126
- 5HT2 receptors, major depression 177
- 5HT2A receptor, Alzheimer's disease 464
- human immunodeficiency virus (HIV) 330
 - antiviral medication psychosis induction 424–6
 - temporal lobe pathology 535–6
- human immunodeficiency virus (HIV), new-onset psychosis 317–19
 - course 318
 - epidemiology 317–18
 - neurochemical abnormalities 319
 - neuropathology 318–19
 - presentation of psychosis 318
 - prognosis 318
 - treatment 319
- hydralazine 411
- hypnotics, psychosis induction 439–40
- ictal psychosis 264–6
 - age of onset 264
 - epidemiology 264
 - genetic factors 266
 - neurophysiological disturbance 265–6
 - presentation 264–5
 - symptoms 265–6
 - treatment 266
- ifosfamide 441
- illusions 285
- imipramine 430
- immigration status, delusional disorder
 - association 128
- immunosuppression
 - brain tumors 308–9
 - psychosis risk 348
 - systemic lupus erythematosus 348
- indomethacin 413
- infections 316
 - definition 316–17
 - diagnostic criteria 316–17
 - fungal 330
 - parasitic 329–30
 - prion diseases 330. *See also* bacterial infections; viral infections
- intellectual disabilities with psychosis 197–8
 - age of onset 201–2
 - autism differential diagnosis 199
 - behavioral symptoms 203–5
 - catatonia 204–5
 - cognitive deficits 206–7
 - cognitive disintegration 200–1
 - congenital syndromes 207
 - course 205–6
 - diagnostic classification systems 200–1
 - diagnostic criteria inconsistency 199–200
 - diagnostic pitfalls 198–9
 - emotional symptoms 203–5
 - epidemiology 198–201
 - epilepsy 208–9
 - gender differences 201–2
 - genetic factors 207–8
 - genetic syndromes 208
 - hysterical symptoms 203–4
 - incidence 201
 - intellectual distortion 200–1
 - negative symptoms 199, 203, 206
 - neuropathology 206–7
 - neuropsychological findings 205
 - obstetric complications 209
 - positive symptoms 203
 - presentation 202–5
 - prevalence 201
 - progression 205–6
 - psychosocial interventions 210
 - schizophrenia
 - diagnosis 204
 - symptoms 198–9
 - sensory impairment 209
 - severity 200–1
 - symptoms 202–5
 - tardive dyskinesia 210
 - thought disorders 198–9
 - treatment 209–11
- interdisciplinary coordination of services, schizophrenia 53
- interferon, psychosis risk 309
- interferon α 441–2

566 Index

- interferon β 342
- interictal psychosis, brief 270–1
 epidemiology 271
 forced normalization 270–1
 neurophysiology 270–1
 presentation 270
 seizures 270–1
- interictal psychosis, chronic 271–9
- interleukin-2 441
- isoniazid 429–30
- isotretinoin 415
- ketamine 526
- kindling
 schizophrenia 259
 traumatic brain injury 258–9
- lamotrigine, bipolar disorder treatment 147
- leucine-rich repeat kinase 2 (*LRRK2*) gene 482
- leukodystrophies 349–57.
See also adrenoleukodystrophy, X-linked
- leukodystrophy, metachromatic 350–3
 age of onset 350
 behavioral disturbance 351
 clinical patterns 350–1
 course 351
 environmental factors 353
 epidemiology 350, 537
 genetic factors 353
 neurochemical abnormalities 353
 neuroimaging 351–2
 neuropathology 351–2
 presentation 350–1
 progression 351
 treatment 353
- levetiracetam
 brain tumors 311
 psychosis risk 309, 420–1
- levodopa 423–4, 494
 drug holidays 424
 Parkinson's disease 492–3, 502
- Lewy bodies
- Lewy body pathology 459, 460
 Parkinson's disease 492–3
 psychosis 497. *See also* dementia with Lewy bodies
- lidocaine 411–12
- lisinopril 411, 412
- lisuride, psychosis risk 309
- lithium
 bipolar disorder treatment 146–8
 brief and acute psychoses 111–12
 cocaine-induced psychosis 387–8
 corticosteroid-induced psychosis 419
 major depression 183
 multiple sclerosis 342, 343
 schizoaffective disorder 87
 traumatic brain injury 255, 256
- lorazepam
 autism with catatonia 241–2
 traumatic brain injury 255
- Lorenzo's oil, X-linked adrenoleukodystrophy 356–7
- Lyme disease 323–5
 course 324–5
 epidemiology 323–4
 neuropathology 325
 presentation 324
 prognosis 324–5
 rapid onset 538–9
 treatment 325
- malaria 329
 rapid onset 538–9
- mania
 bipolar disorder 141
 cannabis psychosis 370–1
 catatonia 234
 cerebrovascular accident 292
 psychotic symptoms 147–8
- MAP2 and MAP5 expression in schizophrenia 65–6
- medication-induced psychosis 406–7
 epidemiology 537. *See also* named drugs
- mefloquine 427
- MELAS syndrome, cerebrovascular accident 297–8
- memantine
 Alzheimer's disease 465–6
 sensory impairment with tactile hallucinations 526
- memory
 disconnection syndrome 297
 impairment 541
- mental retardation 538–9
 schizophrenia 42
- methamphetamine 392–3
- methamphetamine-induced psychosis 5–6, 393
 age of onset 394
 brain changes 396–8
 cognitive impairment 395–6
 course 396
 delusions 394–5
 epidemiology 393–4, 536
 hallucinations 394–5
 neurochemical abnormalities 398–9
 neuroimaging 396–8
 neuropathology 396–8
 presentation 394–6
 progression 396
 risk factors 400
 schizophrenia 400
 stress 399
 symptoms 394–6
 treatment 400–2
- methylphenidate 434
- methylprednisolone 347–9
- metyrosine 226
- mifepristone 183–4
- mitoxantrone 342
- mood congruence/incongruence with psychotic symptoms 162–3
- mood disorders

567 Index

- bipolar disorder 140–1
- bipolarity in brief psychotic disorder/
schizophreniform disorder 104
- delusional disorder comorbidity 122
- epidemiology 536
- schizoaffective disorder 82–3, 88–9
- mood stabilizers, bipolar disorder treatment
146–8
- multiple sclerosis 338–43
 - age of onset 338
 - antipsychotics 343
 - axonal pathology 341
 - bipolar disorder association 146
 - brain changes 339–41
 - carbamazepine 343
 - corticosteroids 342
 - course 339
 - delusions 338–9
 - depression 338, 342
 - environmental factors 341–2
 - genetic factors 341
 - glutamate toxicity 341
 - hallucinations 338–9
 - haloperidol 343
 - interferon β 342
 - lithium 343
 - neurochemical abnormalities 341
 - neuroimaging 339–40
 - neuropathology 339–40
 - presentation 338–9
 - prevalence 338
 - progression 339
 - suicide risk 338
 - symptoms 338–9
 - T lymphocytes 339
 - temporal lobe pathology 535–6
 - treatment 342–3
 - viral infections 341–2
- muscle relaxants, psychosis induction 438–9
- N-acetylaspartate (NAA) 144, 460
- negative affect 540–1
- neural networks, traumatic brain injury 259
- neuregulin 1 (NRG1) gene 27
 - Alzheimer's disease 462, 463
- neuritic plaques 459
 - dementia with Lewy bodies 480
- neurobiological syndrome 7–10, 544–5
 - symptoms 544–5
- neurochemical imbalance 547–8
- neurocysticercosis 329–30
- neurofibrillary tangles 459
 - dementia with Lewy bodies 480
- neuroleptic malignant syndrome 241
 - intellectual disabilities with psychosis 210
- risk with AIDS 425–6
- neuroleptics
 - cannabis psychosis 376–7
 - cocaine-induced psychosis 387–8
 - multiple sclerosis 342
 - schizophrenia 68
 - traumatic brain injury 254–6
- neurological syndromes 7–8
- neuronal networks 548
- neuronal pruning 8
- neurontin 525
- neuropsychological deficits 550
- neurosyphilis 327
 - neuropathology 328
 - paretic 327–8
- neurotransmitter systems 542, 548
- nevirapine 425
- non-affective psychoses, other 108
- non-steroidal anti-inflammatory drugs (NSAIDs),
psychosis induction 413–14
- obsessions, autism with catatonia 240–1
- obsessive compulsive disorder 536
- obstetric complications
 - intellectual disabilities with psychosis 209
 - schizophrenia 49, 209
- olanzapine 51
 - Alzheimer's disease 464–5
 - bipolar disorder treatment 147
 - brain tumor psychosis 310–1
 - cannabis psychosis 376–7
 - methamphetamine-induced psychosis 401, 402
 - Parkinson's disease-induced psychosis 504
 - schizoaffective disorder 87
 - schizophrenia 69
 - traumatic brain injury 255
 - X-linked adrenoleukodystrophy 357
- oncology patients, adjuvant therapy 440–2
- ondansetron
 - methamphetamine-induced psychosis 400–1
 - Parkinson's disease-induced psychosis 505
- opioids 526
- P50 sensory gating deficiencies, cocaine-induced
psychosis 387
- P300 event-related potentials, major depression
with psychosis 175
- paranoia
 - bupropion psychosis 407–8
 - cannabis psychosis 370–1
 - cocaine-induced psychosis 387
 - herbal medication 434
 - stimulants 434
- paranoid personality disorder, delusional disorder
association 127–8
- paraphrenia 60–1
- parasitic infections 329–30
- parkinsonian drugs
 - adjustment 502
 - psychosis induction 422–4
- parkinsonism 492
 - dementia with Lewy bodies 475–6
- Parkinson's disease 422–4
 - visual hallucinations 524
- Parkinson's disease-related psychosis 492–3
 - age of onset 490, 492, 495
- Parkinson's disease-related psychosis (cont.)

568 Index

- behavioral management 501
- brain changes 491, 498
- characteristics 495–7
- clinical management
- co-morbid conditions 496–7
- cortical activity
- development model
- epidemiology 490, 494–5, 537
- genetic factors 491, 498
- management 500–5
- medication adjustment 502
- neurobiological model 499–500
- neurochemistry 491, 497–8
- neuropathology 490, 492–3, 497
- presentation 490
- progression 490
- psychosis 493–4
- regional cortical activity 498
- risk factors 495–6
- sequelae 496–7
- symptoms 495
- treatment 491–3
- pemoline 434
- pergolide 492–3
- perphenazine
 - bipolar disorder treatment 147
 - major depression therapy 183
 - Parkinson's disease-induced psychosis 502
- personality disorder, borderline 161–2
- pervasive development disorders (PDDs)
 - 235
 - categories 235–6
 - childhood-onset schizophrenia 235–7
 - epidemiology 536
- petit mal 265
- phantom pain, sensory impairment with psychosis
 - 517–18, 521–4
 - treatments 525–6
- pheniramine 436–7
- phenobarbital, psychosis induction 420
- phenothiazine 348–9
- phenytoin 420
- pimozide
 - delusional disorder 126, 130
 - Fregoli's syndrome 291
- pituitary tumors 308, 310–1
- polypharmacy, late life schizophrenia
 - 67–8
- post traumatic stress disorder 536
- posterior fossa atrophy 207
- postictal psychosis 266–9
 - active inhibition 269
 - dopamine mechanisms 269
 - epidemiology 267
 - neurochemistry 269
 - neurophysiology 269
 - pathogenesis 268
 - predisposing factors 267–9
 - presentation 267–9
 - prognosis 269
 - treatment 269
- post-partum psychosis, bipolar disorder
 - association 146
- Prader–Willi syndrome, psychotic symptoms 208
- pramipexole, Parkinson's disease 492–3
- prazosin 411
- premorbid 543
- prepulse inhibition deficit
 - schizophrenia 225–6
 - velo-cardio-facial syndrome 225–6
- primary addiction hypothesis 374–5
- prion diseases 330
- procainamide 411–12
- PRODH gene, schizophrenia 225
- prolactin, brain tumors 306
- promethazine 436–7
- pseudopolymelia 288
- psychiatric disorders
 - brain tumors 303–4
 - premorbid 543
- psychoeducational interventions, schizophrenia
 - 29–30, 69–70
- psychogenic psychoses, brief and acute psychoses
 - 110
- psychomotor disturbance, major depression 161, 163
- psychosis
 - chronic 539
 - conceptualization 7–9
 - disease virulence 539
 - episodic 539
 - etiology 3, 550
 - imbalances in systems 546–7
 - modified conceptual framework 545–9
 - not otherwise specified in schizophrenia 45
 - rapid onset 538–9
 - reactive in brief and acute psychoses 110
- psychosocial interventions in schizophrenia 29, 31–2, 51, 69–70
- psychotic disorders
 - diagnostic criteria 4
 - primary 286
- quetiapine
 - Alzheimer's disease 464–5
 - Parkinson's disease-induced psychosis 503–4
 - schizoaffective disorder 87
 - schizophrenia 69
 - traumatic brain injury 255
- quinidine 411–12
- rasagiline 493
- reactive psychoses in brief and acute psychoses
 - 110
- reduplicative amnesia, traumatic brain injury 297
- reduplicative paramnesia 288–90
- reserpine 411
- retinoids, psychosis induction 415–16
- Rett's disorder 235–6
- risperidone 51
 - Alzheimer's disease 464–5
 - bipolar disorder treatment 147
 - cerebrovascular accident 298

- epilepsy with schizophrenia-like psychosis 278
 - methamphetamine-induced psychosis 401
 - Parkinson's disease-induced psychosis 504
 - schizoaffective disorder 87
 - schizophrenia 68–9
 - systemic lupus erythematosus 348–9
 - traumatic brain injury 255
 - rivastigmine
 - dementia with Lewy bodies 483
 - Parkinson's disease-induced psychosis 504–5
 - ropinirole 492–3
 - Rorschach Schizophrenia Index 240
 - St John's wort 408
 - schizoaffective disorder 78–80
 - age of onset 81–2
 - atypical antipsychotics 87–8
 - cannabis psychosis 372
 - children 80–1
 - clinical presentation 82–3
 - diagnosis 88
 - early descriptions 79–80
 - differential diagnosis 81
 - early descriptions 79–80
 - electrophysiology 85
 - epidemiology 80–4, 535
 - event-related potentials 85
 - functional outcomes 83
 - gender 82
 - genetic factors 86–7, 145, 543
 - growth hormone 85–6
 - incidence 80–1
 - mood disorders 82–3, 88–9
 - natural history 83–4
 - neurobiology 84–6
 - neurochemistry 86
 - neuroendocrinology 85–6
 - neuroimaging 84–5
 - neuropsychological performance 84
 - prevalence 80–1
 - psychosis 88–9
 - thought disorders 82
 - treatment 87
 - schizoid traits, cannabis psychosis 376
 - schizophrenia
 - age of onset 17–18, 43
 - late life 60–1
 - velo-cardio-facial syndrome 221
 - antipsychotic medication 68
 - atypical antipsychotics 50–1, 68–9
 - autism association 237–9
 - brain abnormalities 24–5, 47–8, 143–4
 - brief and acute psychosis differential diagnosis 106–7
 - cannabis psychosis 372, 376
 - care levels 49–50
 - children 39–40
 - age of onset 43, 538
 - autism symptoms 240
 - comorbidity 41–2
 - course 46–7
 - ethnicity 42–3
 - gender distribution 41
 - genetic factors 48–9
 - neurochemical abnormalities 48
 - neuropathology 47–8
 - obstetric complications 49
 - presentation 43–5
 - prevalence 40–1
 - progression 46–7
 - treatment 49–53
- chromosome 22q 218–19
- microdeletion 220
- clinical trials 29
- cocaine-induced psychosis 384
- cognitive deficits 21, 44–5, 61–2
 - intellectual disabilities with psychosis 206–7
- cognitive heterogeneity 21
- cognitive rehabilitation 32
- cognitive testing 19
- cognitive–behavioral interventions 30–1
- comorbidity
 - children 41–2
 - conditions 16
 - young people 41–2
- compliance with medication 69
- comprehensive multimodal approach 51
- COMT gene 225
- cost of care 49–50
- course 19, 21–4, 538–9
 - children 46–7
 - intellectual disabilities with psychosis 205–6
 - late life 63–4
 - young people 46–7
- deficit 20
- delusions 43–4
- diagnosis 5–7, 15–16
 - intellectual disabilities with psychosis 204
 - late life 62–3
- diagnostic criteria 4, 16, 43, 61
- diagnostic methods 44
- diathesis stress model 8
- dopamine hypothesis 24, 26
- drug therapies 28, 50–1
- early phase 29–30
- epidemiology 16–17, 535
- epilepsy association 208–9, 262
- ethnicity
 - children 42–3
 - chromosome 22q microdeletion 218–20
 - young people 42–3
- evidence-based treatments 29
- expressed emotion 53
- familial stress 67
- family services 53
- first break/episode 18
- gender distribution
 - children 41
 - late life 67, 70
 - young people 41
- general deficit syndrome 19, 20
- genetic factors 26–7, 145, 543
 - children 48–9

- schizophrenia (cont.)
- intellectual disabilities with psychosis 207–8
 - late life 66
 - young people 48–9
 - geriatric 60
 - glutamate decarboxylase 66
 - incidence 16, 17, 201
 - intellectual functioning 22–3
 - interdisciplinary coordination of services 53
 - kindling 259
 - late life 59–60
 - age of onset 60–1
 - brain imaging 64–5
 - course 63–4
 - diagnosis 62–3
 - gender distribution 67, 70
 - genetic factors 66
 - heterogeneity 64
 - neurochemistry 65–6
 - neuropathology 64–5
 - PANSS scale 62
 - polypharmacy 67–8
 - presentation 61–3
 - progression 63–4
 - treatment 67–70
 - life events 67
 - life span 63–4
 - long-term course 23
 - maintenance phase 31–2
 - MAP2 and MAP5 expression 65–6
 - mental retardation 42
 - methamphetamine-induced psychosis 400
 - middle-age onset 61
 - molecular signaling pathway abnormalities 65–6
 - mortality 16, 63–4
 - neurochemical abnormalities 24–6, 144
 - children 48
 - late life 65–6
 - young people 48
 - neurocognitive phenotype 226
 - neurological functioning 48
 - neuropathology 24–6, 143–4
 - children 47–8
 - intellectual disabilities with psychosis 206–7
 - late life 64–5
 - young people 47–8
 - neuropsychological deficits 44–5
 - intellectual disabilities with psychosis 205
 - obstetric complications 209
 - children 49
 - young people 49
 - outcome 46–7
 - PANSS scale 62
 - premorbid period 21–3, 46
 - prepulse inhibition deficit 225–6
 - presentation 6–7, 18–21
 - children 43–5
 - late life 61–3
 - young people 43–5
 - prevalence 201
 - children 40–1
 - increase in intellectual disabilities with psychosis 201
 - young people 40–1
 - PRODH gene 225
 - progression 21–4, 538–9
 - children 46–7
 - intellectual disabilities with psychosis 205–6
 - late life 63–4
 - young people 46–7
 - psychoeducational interventions 29–30, 69–70
 - psychosis not otherwise specified 45
 - psychosocial functioning 22–3
 - psychosocial interventions 29, 31–2, 51, 69–70
 - psychotic bipolar similarities 143–4
 - schizoaffective disorder
 - differential diagnosis 81
 - relationship 78–9
 - sensitization 259
 - smooth pursuit eye tracking deficit 226
 - social maladjustment 67
 - social skills training 31–2
 - somatic treatments 28
 - stabilization phase 30–1
 - subgroups 17
 - symptoms 18–19
 - first rank 43–4, 105, 198–9
 - intellectual impairment with psychosis 202–3
 - synapse abnormalities 65–6
 - treatment 27–32
 - children 49–53
 - early phase 29–30
 - intellectual disabilities with psychosis 209–11
 - late life 67–70
 - maintenance phase 31–2
 - stabilization phase 30–1
 - young people 49–53
 - University of Hawaii Child and Adolescent Thought Disorders Program 51–3
 - Usher syndrome association 209
 - velo-cardio-facial syndrome 219–22
 - vulnerability 8–9
 - white matter abnormalities 143
 - young people 39–40
 - age of onset 43
 - comorbidity 41–2
 - course 46–7
 - ethnicity 42–3
 - gender distribution 41
 - genetic factors 48–9
 - neurochemical abnormalities 48
 - neuropathology 47–8
 - obstetric complications 49
 - presentation 43–5
 - prevalence 40–1
 - progression 46–7
 - treatment 49–53
 - schizophrenia-like psychosis
 - very late-onset 60–1. *See also* epilepsy with schizophrenia-like psychosis
 - schizophreniform disorder
 - age at onset 103
 - amino acids 108

571 Index

- antipsychotic medication 111
- anxiety 105
- cerebrovascular accident 296
 - course 105–7
 - criteria 97–101
 - diagnostic systems 97–101
 - differential diagnosis 106–7
 - duration of treatment 111
 - epidemiology 101–3
 - genetics 108–9
 - incidence 101–2
 - intellectual disabilities with psychosis 204
 - mood bipolarity 104
 - neurochemical abnormalities 108
 - neuroimaging 107
 - neuropathology 107
 - outcome 106
 - presentation 103–5
 - prevalence 101–2
 - progression 105–7
 - psychogenic 110
 - psychotic episode duration 105–6
 - reactive 110
 - symptoms 104
 - treatment 110–12
- schizophreniform disorders
 - developing countries 102
 - gender 102–3
- schizotypy, velo-cardio-facial syndrome 219–20
- scopolamine 430
- seizure disorders
 - traumatic brain injury 251–2. *See also* epilepsy
- seizures 263
 - absence 264, 265
 - behavioral disturbances 266–7
 - brief interictal psychosis 270–1
 - cerebrovascular accident 296–7
 - risk with antipsychotics 279
 - termination by active inhibition 269
- selective serotonin reuptake inhibitors (SSRIs)
 - Alzheimer's disease 465
 - major depression 182–3
 - psychosis induction 408
- selegiline
 - methamphetamine-induced psychosis 400–1
 - Parkinson's disease 493, 502
 - psychosis induction 423–4
- sensitization
 - schizophrenia 259
 - traumatic brain injury 258–9
- sensory deprivation 546
- visual hallucinations 524
- sensory impairment with psychosis 514
 - age of onset 515–16
 - course 518–19
 - epidemiology 514–15
 - genetic factors 523–4
 - intellectual disabilities 209
 - neurochemical abnormalities 523
 - neuropathology 519–23
 - presentation 516–18
 - progression 518–19
 - treatment 525–6
- serine, brief and acute psychoses 108
- serotonergic system, bipolar disorder 144
- serotonin and norepinephrine combined
 - antidepressants 408
- serotonin receptor 2A 464
- sertraline, psychosis induction 409
- sex chromosome anomalies, psychotic symptoms 208
- sleep disorders
 - dementia with Lewy bodies 477
 - Parkinson's disease-related psychosis 496
- sleep studies, major depression with psychosis 175–6
- smooth pursuit eye tracking deficit
 - schizophrenia 226
 - velo-cardio-facial syndrome 226
- social maladjustment, schizophrenia 67
- social skills training, schizophrenia 31–2
- sodium valproate 343
- somatophrenia 288
- speech in autism 239–40
- spirochetes 322
- status epilepticus 264
 - nonconvulsive 264, 266
 - partial complex 264
 - petit mal 265
 - simple partial 264
- steroids, psychosis induction 418–19, 542
- stimulants, psychosis induction 433–4
- stress, methamphetamine-induced psychosis 399
- stroke. *See* cerebrovascular accident, psychosis
 - after
- substance abuse 5–6
 - angel's trumpet 431
 - epidemiology 536. *See also* cannabis psychosis; cocaine; methamphetamine
- substance-induced psychotic disorder, diagnostic criteria 4–5
- suicide
 - major depression with psychosis 165, 166
 - multiple sclerosis 338
- synapses, schizophrenia 65
- syphilis 326–9
 - course 327–8, 538–9
 - epidemiology 326
 - neuropathology 328
 - presentation 327
 - prognosis 327–8
 - tertiary 327
 - treatment 328–9
- systemic lupus erythematosus 343–9
 - temporal lobe pathology 535–6
- systemic lupus erythematosus, neuropsychiatric syndromes 344
 - age of onset 345
 - autoantibodies 346–7
 - brain changes 346
 - course 345–6
 - epidemiology 344–5
 - genetic factors 347
 - glutamate toxicity 347

572 Index

- systemic lupus erythematosus, neuropsychiatric syndromes (cont.)
 lupus activation suppression 348–9
 neurochemistry 346–7
 neuroimaging 346
 neuropathology 346
 presentation 345
 progression 345–6
 symptoms 345
 treatment 347–9
- T lymphocytes, multiple sclerosis 339
Taenia solium (tapeworm) 329–30
 tardive dyskinesia
 human immunodeficiency virus treatment 319
 intellectual disabilities with psychosis 210
 major depression therapy 183
 thiazide diuretics 412
 thioridazine 502
 thought disorders 19, 540
 autism 238–9
 bipolar disorder 140–1
 intellectual disabilities with psychosis 198–9
 schizoaffective disorder 82
 tick-borne disease 323–4
 tinnitus 523
 tocainide 411–12
 topiramate 400–1
 transcutaneous electrical nerve stimulation (TENS) 526
 transmissible spongiform encephalopathies 330
 treatment of psychosis 544, 549–53
Treponema pallidum 327–9
 tricyclic antidepressants
 major depression 180–2
 psychosis induction 408, 410, 430
 trifluoperazine 290, 291
 Fregoli's syndrome 291
 systemic lupus erythematosus 348–9
 trihexylphenidyl 493
 tuberculosis medication 429–30
- University of Hawaii Child and Adolescent Thought Disorders Program 51–3
 Usher syndrome
 intellectual disabilities with psychosis 209
 schizophrenia association 209
- valproic acid
 brain tumor psychosis 310
 psychosis induction 420
 traumatic brain injury 255
 visual hallucinations 525
- vascular risk factors, major depression with psychosis 174–5
 velo-cardio-facial syndrome 208, 218–19
 age of onset 220–1, 538
 behavioral phenotype 219–21
 bipolar disorder 220–2
 brain
 changes 222–3
 development 223
 chromosome 22q 218–19
 microdeletion 218–19
 COMT enzyme targeting 226
 COMT gene 224–5, 542–3
 course 221–2
 depression 221–2
 dopaminergic pathways 224
 epidemiology 219–20, 536
 genetic factors 224–5, 542–3
 imaging 222
 neuroanatomy 222–3
 neurochemical abnormalities 224
 neurocognitive phenotype 226
 prepulse inhibition deficit 225–6
 presentation 220–1
 progression 221–2
 psychiatric disorder risk 219–20
 psychosocial dysfunction 221–2
 schizophrenia risk 219–22
 schizotypy risk 219–20
 smooth pursuit eye tracking deficit 226
 treatment 226
 ventricular cerebrospinal fluid 223
 white matter 222–3
 ventricle-to-brain ratio, major depression with psychosis 174
 very long chain fatty acids (VLCFA) 355–6
 Lorenzo's oil 356–7
 vigabatrin 420–2
 violence, delusional disorder 121
 viral infections 316–22
 multiple sclerosis 341–2
- white matter
 brain changes 143, 223, 541–2
 schizophrenia 143
 velo-cardio-facial syndrome 222–3
- zaleplon 439, 440
 ziprasidone
 bipolar disorder treatment 147
 cannabis psychosis 376–7
 schizoaffective disorder 87
 zolpidem 439, 440